Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
Front Immunol. 2021 Mar 16;12:652973. doi: 10.3389/fimmu.2021.652973. eCollection 2021.
Most chronic spontaneous urticaria (CSU) patients are female, and pregnancy can aggravate the disease activity of patients, but little is known about the efficacy and safety of omalizumab in pregnant CSU patients. We report two pregnant CSU patients treated with omalizumab and review the published information on omalizumab treatment during 11 pregnancies. The outcomes reported on patients with known pregnancies showed they had normal pregnancies and healthy babies as well as complete control of their CSU. The two new cases we reported support the view that omalizumab could be an effective and safe treatment option for pregnant and breastfeeding CSU patients. Further high-quality studies need to be carried out in order to obtain more information on the long-term efficacy and safety of the use of omalizumab during pregnancy in patients with chronic urticaria, including CSU.
大多数慢性自发性荨麻疹（CSU）患者为女性，且妊娠可加重患者的疾病活动度，但奥马珠单抗治疗妊娠 CSU 患者的疗效和安全性知之甚少。我们报告了 2 例接受奥马珠单抗治疗的妊娠 CSU 患者，并复习了 11 例妊娠期间奥马珠单抗治疗的相关文献。关于已知妊娠患者的结局报道显示，她们均顺利妊娠，新生儿健康，CSU 完全缓解。我们报告的 2 例新病例支持奥马珠单抗可能是妊娠和哺乳期 CSU 患者的一种有效且安全的治疗选择的观点。需要开展更多高质量研究，以获取关于慢性荨麻疹患者（包括 CSU 患者）在妊娠期间使用奥马珠单抗的长期疗效和安全性的更多信息。
